Indefinite Delivery Contract SPE2DX16D9957

Award Date 4/14/25
Last Date to Order 11/13/26
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV award SPE2DX24D9950 is a single-award indefinite delivery contract (IDC) with a ceiling value of $499,999,999 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, which runs through December 31, 2025, is part of the DLA's Medical Supply Chain program and allows the agency to issue firm fixed-price delivery orders for a wide range of pharmaceutical products to support the...
The federal contract IDV award SPE2DB24D9803 is a single-award Indefinite Delivery Contract (IDC) with a ceiling value of $499,999,999 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, which runs through December 31, 2025, allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health...
The federal contract IDV award SPE2DX15D6907 is an Indefinite Delivery Contract (IDC) between the Defense Logistics Agency (DLA) and the prime contractor DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $4,999,999.00 single-award IDC, awarded on March 23, 2017, covers the supply of a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support...
The federal government has awarded an Indefinite Delivery Contract (IDC) valued at $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, awarded by the Defense Logistics Agency (DLA) under the SPE2DB program, covers the delivery of a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military health facilities nationwide. The IDC enables the DLA to issue firm fixed-price...
The federal contract IDV award SPE2DX15D9000 is a single-award indefinite delivery contract (IDC) with the Defense Logistics Agency (DLA) awarded to the prime contractor DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $499,493,731 IDC, which runs through November 12, 2025, allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support the recurring medical supply needs of...
The federal contract IDV award to DMS Pharmaceutical Group Inc. is a single-award indefinite delivery contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program. The contract has a ceiling value of $499,999,999 and runs through December 31, 2025. Under this IDC, DMS Pharmaceutical Group, a woman-owned small business, provides a comprehensive range of pharmaceutical products and medical supplies to fulfill the recurring medical needs of military health facilities worldwide....
The federal contract IDV award is a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999, awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The contract, under the SPE2DB program, covers a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The...
The federal contract IDV award is a single-award indefinite delivery contract (IDC) between the Defense Logistics Agency (DLA) and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, awarded on June 6, 2024, provides the DLA with a vehicle to issue firm fixed-price delivery orders for a wide range of pharmaceutical products to meet the recurring medical supply needs of military health facilities worldwide. The contract, under the SPE2DB...
The federal contract IDV award described is a single-award Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The contract, awarded by the Defense Logistics Agency (DLA) under the SPE2DB program, has a ceiling value of $499,999,999 and runs through December 31, 2025. Through this IDC, DMS Pharmaceutical Group provides a comprehensive range of pharmaceutical products and medical supplies to fulfill...
This single-award indefinite delivery contract with a potential value of up to $499,999,999 was awarded to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business, by the Defense Logistics Agency. The contract, under the SPE2DB program, enables the DLA to issue firm fixed-price delivery orders through December 31, 2025 for a broad range of pharmaceutical products to support the recurring medical supply needs of military health facilities globally. Major categories of goods to...

The federal contract IDV award SPE2DX16D9957 is a single-award Indefinite Delivery Contract (IDC) valued at $4,999,999.00 and awarded to the woman-owned small business DMS Pharmaceutical Group Inc. by the Defense Logistics Agency (DLA) under the SPE2DX program. The contract covers the delivery of a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

This IDC enables the DLA to issue firm fixed-price delivery orders for the pharmaceutical items, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain and providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites. The contract has an ultimate completion date of November 13, 2026, and does not utilize any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure this direct federal award.

Generated 6/1/25, 2:46 AM